Lifeport is home to a good number of innovative start-ups in the fields of Health & High Tech. One of these is Aiosyn, based in Nijmegen. This company combines AI and pathology to improve and speed up cancer diagnostics.
Aiosyn, a spin-off from Radboudumc, is developing an AI platform that helps pathologists reach faster and more accurate diagnoses. Recent investments from LUMO Labs and Oost NL are enabling this fledgling company to get off to a flying start. Patrick de Boer is the co-founder and CEO of the company. He talks about the enormous value this platform can offer to both pathologists and patients.
What exactly does Aiosyn do?
“Aiosyn develops algorithms that support pathologists in diagnosing diseases such as cancer. By using our algorithms, pathologists can improve the quality and efficiency of diagnostics. The synergy between the pathologist and AI delivers better quality and, consequently, the greatest value for the patient.”
“Aiosyn’s aim is to make our software available anywhere and at any time, thereby improving the quality of diagnoses worldwide. By using our algorithms, even less experienced pathologists can be brought up to a much higher standard. If we achieve this, our mission will have been accomplished.”
How did this idea originate?
“During a meeting, I met Professor Jeroen van der Laak. He heads the Computational Pathology department at Radboudumc in Nijmegen. I myself have been an entrepreneur and consultant in the Life Sciences & Health sector and have spent many years helping biotech and medtech companies with strategy and financing. The combination of an entrepreneur and a scientist seemed to us to be a good starting point for a company.”
“Jeroen told me that he and his team have been working for over fifteen years on developing algorithms to support pathologists in carrying out diagnostics. Thanks in particular to the introduction of ‘deep learning’ and the improved computing power of computers, his work has really taken off in recent years. The results of his research are very promising. We decided together that we also wanted to develop these into a product so that we could implement them in patient care. That was also when my colleagues David Tellez and Wouter Bulten joined the team.”
Why is this so important?
“The healthcare sector is under pressure. The number of pathologists is set to decline further in the coming years, whilst the workload is only increasing due to the high burden of disease. It is also becoming increasingly difficult to find qualified analysts.”
“At the same time, the number of publications demonstrating the added value of AI in diagnosing cancer is growing. Furthermore, Jeroen’s team has published a number of important articles demonstrating that the combination of pathologists and AI leads to better results. If you have the potential to improve both the efficiency and the quality of care, you have a solid foundation for a healthy business.”
What challenges do you face?
“To ‘train’ our algorithms, we need a lot of pathology images. Obtaining high-quality datasets is therefore Aiosyn’s main challenge. We are not alone in this. All AI companies in the medical sector face the same problem. At present, there are too few initiatives to make data available on a large scale for research and the development of algorithms. We therefore need to collaborate with various hospitals to gain access to data.”
“A second challenge is the digitisation of laboratories. At present, the majority of pathology labs still operate using analogue microscopes. However, to apply AI, you need a digital working environment. The market is therefore still developing. The advantage, though, is that you can be one of the first to offer a unique solution.”
What are your plans for the future?
"Aiosyn is developing a diagnostic platform with both clinical algorithms and algorithms that can improve laboratory workflow. We will implement our algorithms in the daily workflow of the pathologist and the laboratory. Only by offering our AI in the standard workflow will our users experience the maximum results of AI."
What else would you like to add?
“Personally, I am a firm believer in a learning healthcare system. The healthcare sector generates an enormous amount of data, and we all pay for it. We should be keen to utilise that data to provide better care for the patients of the future. Unfortunately, we are not making sufficient use of that potential. My personal aim is also to contribute to making data available for research and development, so that researchers and companies can create solutions for the future.”
Source: Innovation Origins


